Mithra Announces Presentation of Donesta® Results at the International Menopause Society’s 16th World Congress

Liège, Belgium, 8 June 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today presents its Phase IIb results for Donesta® at the International Menopause Society’s 16th World Congress on menopause (Vancouver, Canada).

Donesta® is Mithra’s next-generation hormone therapy (HT) product candidate with oral administration of Estetrol (E4) for the treatment of Vasomotor Symptoms (VMS), and in particular hot flushes relief, in post-menopausal women. Mithra recently announced positive top-line results, showing a significant improvement on the frequency and severity of hot flushes, as well as on secondary menopausal symptoms such as VVA, while indicating a beneficial safety profile.